MannKind Co. (MNKD) VP Stuart A. Tross Purchases 39,840 Shares

MannKind Co. (NASDAQ:MNKD) VP Stuart A. Tross acquired 39,840 shares of MannKind stock in a transaction on Thursday, December 21st. The shares were purchased at an average price of $2.52 per share, for a total transaction of $100,396.80. Following the completion of the acquisition, the vice president now directly owns 59,840 shares in the company, valued at $150,796.80. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

MannKind Co. (NASDAQ:MNKD) traded down $0.11 during trading on Friday, hitting $2.41. The stock had a trading volume of 4,828,200 shares, compared to its average volume of 4,005,895. The company has a debt-to-equity ratio of -0.43, a current ratio of 0.31 and a quick ratio of 0.28. The firm has a market cap of $271.02, a PE ratio of -8.93 and a beta of 3.07. MannKind Co. has a 52-week low of $0.67 and a 52-week high of $6.96.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.11). The business had revenue of $2.04 million during the quarter, compared to analyst estimates of $2.56 million. MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. The firm’s revenue for the quarter was down 98.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.30 EPS. equities research analysts forecast that MannKind Co. will post -1.13 EPS for the current year.

Several institutional investors have recently bought and sold shares of MNKD. Macquarie Group Ltd. acquired a new stake in shares of MannKind in the 3rd quarter worth $156,000. Wells Fargo & Company MN boosted its position in shares of MannKind by 51.5% in the 3rd quarter. Wells Fargo & Company MN now owns 89,951 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 30,589 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in shares of MannKind in the 3rd quarter worth $219,000. Bank of New York Mellon Corp boosted its position in shares of MannKind by 30.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 108,380 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 25,125 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of MannKind in the 3rd quarter worth $270,000. 12.11% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have issued reports on MNKD. BidaskClub cut MannKind from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research cut MannKind from a “hold” rating to a “sell” rating in a research report on Wednesday, December 13th. ValuEngine raised MannKind from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th. HC Wainwright reaffirmed a “buy” rating on shares of MannKind in a research report on Wednesday, November 8th. Finally, Maxim Group reaffirmed a “hold” rating on shares of MannKind in a research report on Wednesday, November 1st. Five analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Sell” and an average price target of $0.92.

WARNING: “MannKind Co. (MNKD) VP Stuart A. Tross Purchases 39,840 Shares” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/22/mannkind-co-mnkd-vp-stuart-a-tross-purchases-39840-shares.html.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit